Share on StockTwits

A number of stock research firms have changed their ratings and price targets for Gilead Sciences (NASDAQ: GILD) during the last seven days:

  • Gilead Sciences is now covered by analysts at Argus. They set a “buy” rating and a $110.00 price target on the stock.
  • Gilead Sciences is now covered by analysts at FBR Capital Markets. They set an “outperform” rating and a $125.00 price target on the stock.
  • Gilead Sciences is now covered by analysts at RBC Capital. They set an “outperform” rating on the stock.
  • Gilead Sciences had its price target raised by analysts at Cowen and Company from $95.00 to $105.00. They now have an “outperform” rating on the stock.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at 101.28 on Wednesday. Gilead Sciences, Inc. has a one year low of $57.31 and a one year high of $101.65. The stock’s 50-day moving average is $90.94 and its 200-day moving average is $81.53. The company has a market cap of $153.1 billion and a price-to-earnings ratio of 22.82.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Wednesday, July 23rd. The company reported $2.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the previous year, the company posted $0.50 earnings per share. The company’s revenue for the quarter was up 136.1% on a year-over-year basis. On average, analysts predict that Gilead Sciences, Inc. will post $8.00 earnings per share for the current fiscal year.

In other Gilead Sciences news, CFO Robin L. Washington sold 33,556 shares of Gilead Sciences stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $95.56, for a total value of $3,206,611.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.